BIOTRON LIMITED — Investor Presentation 2015

May 27, 2015

==> picture [227 x 36] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

28 May 2015

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(11 pages by email)

Dear Madam

PRESENTATION TO INVESTORS

I attach a PowerPoint presentation as presented by Biotron Limited's Managing Director, Dr Michelle Miller, to investors.

Yours sincerely

==> picture [105 x 67] intentionally omitted <==

Peter J. Nightingale Company Secretary pjn8116

BIOTRON
LIMITED (ASX:BIT) Mid-­‐Clinical
Stage
An=viral Drug
Development
Company

Broker
Meet
Biotech May
2015

Dr
Michelle
Miller Managing
Director +61
412
313329 mmiller@biotron.com.au www.biotron.com.au

==> picture [720 x 50] intentionally omitted <==

This
presenta6on
may
contain
forward-­‐looking
statements
with
respect
to
the
financial
condi6on, results
and
business
achievements/performance
of
Biotron
Limited
(ACN
086
399
144)
and
certain of
the
plans
and
objec6ves
of
its
management.
These
statements
are
statements
that
are
not historical
facts.
Words
such
as
“should”,
“expects”,
“an6cipates”,
“es6mates”,
“believes”
or
similar expressions,
as
they
relate
to
Biotron
Limited,
are
intended
to
iden6fy
forward-­‐looking
statements. By
their
nature,
forward-­‐looking
statements
involve
risk
and
uncertainty
because
they
reflect Biotron’s
current
expecta6ons
and
assump6ons
as
to
future
events
and
circumstances
that
may
not prove
accurate.
There
is
no
guarantee
that
the
expected
events,
trends
or
results
will
actually occur.
Any
changes
in
such
assump6ons
or
expecta6ons
could
cause
actual
results
to
differ materially
from
current
expecta6ons.

==> picture [720 x 50] intentionally omitted <==

• Mid-clinical stage antiviral drug development company

• New mode-of-action, first-in-class small molecule drugs

• Phase 2 clinical programs for Hepatitis C virus (HCV) and HIV

  • BIT225 has demonstrated clinical activity

  • Seven clinical trials completed; one in progress

• Headquartered in Sydney, Australia

• Experienced management team with pharma and VC background

• Key highlights over last 12 months

• 100% SVR12 (i.e. HCV cure) reported for HIV/HCV G3 Phase 2 trial

• Impact on immune activation reported for HIV Phase 2a trial

• Phase 2, three-month dosing HCV trial fully recruited

• Key patents for BIT225 and other compounds issued in US and other key jurisdictions

• Completion of fully underwritten, oversubscribed $4 million rights issue

Slide
1

INDICATION	COMPOUND	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Hep C	BIT225
HIV/Hep C	BIT225
HIV	BIT225
Next genera=on - HCV	BIT314
Dengue	Leads

Slide
2

**BIT225

–
New
Class
of
HCV
Drug
with
Proven
Clinical
Track
Record**

POLYMERASE/PROTEASE INHIBITORS
e.g.
Sovaldi/ Simeprevir BIT225
-­‐
ASSEMBLY/ BUDDING
INHIBITOR

ü Over
180
people
dosed
with
BIT225 ü Posi6ve
data
recorded
in
all
trials

Only
one
of
its
class
(p7
inhibitor)
in
clinical
trials

ü

ü Independently
shown
to
have
pan-­‐genotype
ac6vity:

ü Ac6ve in
vitro against
all
main
HCV
subtypes ü Shown
to
be
clinically
ac6ve
against
hard-­‐to-­‐treat
HCV G1
(1a
and
1b)
and
G3 ü Poten6al
to
fill
the
gaps
lea
by
other
HCV
drugs,
e.g.
HCV
G3 ü Rela6vely
easy
to
make
and
formulate ü Very
stable
at
room
temperature
–
important
for
supply
chains

Slide
3

• Forecast
  to
  grow
  to
  over
  $19bn
  by
  2016

• 180
  million
  infected
  worldwide
  (3%
  world
  popula6on)

• ~3
  to
  5
  million
  in
  US
  &
  30
  million
  in
  China

• New
  drugs
  have
  demonstrated
  significant
  pricing
  power

• Gilead’s
  Sovaldi
  (Sofosbuvir)
  at
  US$84,000
  for
  a
  12
  week
  course

• Best
  performing
  ‘first
  year’
  sales:
  ~US$10
  billion

• Recent
  new
  HCV
  drug
  combina6ons
  not
  op6mal

• Lengthy
  treatment
  –
  12
  weeks
  or
  more

• Not
  pan-­‐genotypic
  – BIT225
  is
  pan-­‐genotypic in
  vitro

• Not
  as
  effec6ve
  against
  HCV
  G3
  – BIT225
  has
  good
  ac=vity
  against
  HCV
  G3

• Partnering
  s6ll
  ac6ve

• J&J
  partnered
  Achillion
  in
  US$1.1
  bn
  deal
  in
  May
  ‘15;
  Merck
  bought
  Idenix
  for
  US$3.8
  bn
  in
  June
  ‘14

Slide
4

**HIV

–
Towards
a
Cure**

• Infec6on
  rates
  at
  20
  year
  high

• Over
  1.1
  million
  people
  living
  with
  HIV
  in
  the
  USA; 1
  in
  6
  unaware
  of
  diagnosis

• Pa6ents
  need
  to
  stay
  on
  an6retroviral
  drugs
  (ART)

• Industry
  focused
  on
  developing
  drugs
  to
  eradicate
  or
  cure
  HIV infec6on

• Phase
  2a
  trial
  showed
  BIT225
  anacks
  HIV
  in
  macrophage
  cells in vivo ,
  paralleling in
  vitro studies

• Poten6al
  benefits
  on
  immune
  aging
  and
  HIV-­‐associated
  demen6a

• Poten=al
  for
  use
  in
  future
  eradica=on
  treatments

==> picture [643 x 176] intentionally omitted <==

----- Start of picture text -----

A
B
d14
infec6on
&
d21
BIT225
addi6on
In
vitro
Effect
on
HIV
Replica3on
200 Placebo
150
100 +BIT225
50
16 17 19 21 22 23 24 25 26 27 28
Time
(days)
+HIV-­‐1
----- End of picture text -----

==> picture [314 x 18] intentionally omitted <==

----- Start of picture text -----

(A)
Untreated
Controls

(B)
BIT225
treated
cells
----- End of picture text -----

Slide
5

• HCV
  and
  HIV
  are
  high
  growth,
  mul6-­‐billion
  dollar
  markets

• Treatment
  gaps
  remain

• BIT225
  is
  a
  novel
  approach
  with
  demonstrated
  promising
  efficacy
  in
  Phase
  2a/2
  clinical
  trials

• Represents
  a
  new
  class
  of
  direct-­‐ac6ng
  HCV
  drugs

• Poten6al
  to
  fill
  significant
  HCV
  treatment
  gaps

  • HCV
    Genotype
    3

  • HIV/HCV
    co-­‐infected
    pa6ents

  • • Cirrho6c
    pa6ents

• Poten6al
to
eradicate
important
HIV
reservoirs,
plus
may
impact
on
HIV-­‐associated
demen6a

• Flexibility
  to
  combine
  with
  any
  other
  HCV
  and
  HIV
  drug
  combina6ons

• • Significantly
  undervalued
  in
  comparison
  with
  other
  HCV
  companies

Slide
6

• ~~Complete BIT225-008 HCV trial currently in progress~~

• Preliminary
  interim
  data
  expected
  mid-­‐2015

• Inves6ga6onal
  New
  Drug
  applica6on(s)
  (INDs)

• Engaged
  with
  FDA
  -­‐
  pre-­‐IND
  consulta6on
  HCV
  combina6on
  trial
  with
  DAA

• File
  IND
  applica6on(s)
  mid-­‐2015

  • Currently
    comple6ng
    studies
    required
    by
    FDA

• Expand
  earlier
  stage
  drug
  programs
  e.g.
  Dengue
  virus
  when
  funding
  available

• Con6nue
  commercialisa6on
  ac6vi6es
  aimed
  at
  anrac6ng
  partners

• Con6nue
  to
  promote
  company
  to
  local
  and
  interna6onal
  investment
  community

Slide
7

**Key

Financial
Metrics**

Ticker
Code ASX:
BIT Share
Price
(27
May
2015) A
$0.125 Market
cap A
$32
million 12
Month
Trading
Range A
$0.0864
–
0.1832 Shares
Outstanding 279
million Op6ons
(BITO) 50.7
million
$0.12
expiry
30/09/16 A
$2.2
million Cash
Posi6on
(03/2015) (excludes
$1.7
m
received
as
R&D
Tax incen6ve in April
‘15)

Board

Michael
Hoy Non-­‐execu6ve
Chairman Michelle
Miller Managing
Director Susan
Pond Non-­‐execu6ve
Director Rob
Thomas Non-­‐execu6ve
Director Denis
Wade Non-­‐execu6ve
Director

**12

Month
Share
Price
Performance**

12 Month Share Price Performance	12 Month Share Price Performance
Ticker Code	ASX: BIT
Share Price (15 Sept 2014)	A $0.115
Market cap	A $26.3 million
12 Month Trading Range	A $0.075 – 0.315
Shares Outstanding	228 million
Cash Posi6on (06/14)	A $1.76mn

Slide
8